Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
Status:
Unknown status
Trial end date:
2021-05-01
Target enrollment:
Participant gender:
Summary
This will be a 24 month phase IV, randomised, prospective, multicentre, clinical trial of
laser therapy to areas of peripheral retinal ischaemia combined with intravitreal aflibercept
versus intravitreal aflibercept monotherapy. Both arms will have 2mg intravitreal aflibercept
according to a treat and extend protocol.
The specific aim of the study is to test whether laser therapy of peripheral retinal
ischaemia reduces the overall number of intravitreal aflibercept injections required to
control DMO over a 24 month period.